| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Ecabet Sodium (TA-2711; TA2711) is an eye drop used for the treatment of dry eye syndrome. It works by increasing the amount and quality of mucin made by corneal epithelia and conjunctival goblet cells. A glycoprotein called mucin, which is a part of the tear film, lubricates while delaying the loss of moisture from evaporating tears. Additionally, it is advertised in Japan as an oral agent for the management of gastritis and ulcers. Ecabet decreases the survival of H. pylori in the stomach and prevents pepsin activity in the gastric juice of experimental animals.
| Targets |
ROS production; Bacterial; Apoptosis
|
|---|---|
| References |
|
| Molecular Formula |
C20H26NA2O5S
|
|---|---|
| Molecular Weight |
424.46
|
| Elemental Analysis |
C, 56.59; H, 6.17; Na, 10.83; O, 18.85; S, 7.55
|
| CAS # |
86408-72-2
|
| Related CAS # |
Ecabet;33159-27-2
|
| Appearance |
Solid powder
|
| SMILES |
CC(C)C1=C(C=C2C(=C1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)C(=O)[O-])C)S(=O)(=O)[O-].[Na+].[Na+]
|
| InChi Key |
NQQLQPVASUVBKM-MUMAJMNHSA-L
|
| InChi Code |
InChI=1S/C20H28O5S.2Na/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25;;/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25);;/q;2*+1/p-2/t17-,19-,20-;;/m1../s1
|
| Chemical Name |
disodium;(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-6-sulfonato-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate
|
| Synonyms |
Ecabet Sodium; TA-2711; TA-2711E; TA-2711; TA 2711
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 80~100 mg/mL (198.8~248.5 mM)
Ethanol: ~3 mg/mL (~7.5 mM) Water: ~16 mg/mL (~39.8 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3559 mL | 11.7797 mL | 23.5593 mL | |
| 5 mM | 0.4712 mL | 2.3559 mL | 4.7119 mL | |
| 10 mM | 0.2356 mL | 1.1780 mL | 2.3559 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00667004 | Completed | Drug: ecabet ophthalmic solution Drug: placebo |
Dry Eye Disease | Bausch & Lomb Incorporated | March 22, 2008 | Phase 2 |
| NCT00370747 | Completed | Drug: Ecabet Drug: Placebo |
Dry Eye Syndromes | Bausch & Lomb Incorporated | September 2006 | Phase 2 |
| NCT00198536 | Completed | Drug: Vehicle Drug: Ecabet 2.83% |
Dry Eye Syndromes | Bausch & Lomb Incorporated | April 2005 | Phase 2 Phase 3 |
| NCT01039558 | Completed | Drug: placebo Drug: ecabet sodium |
Gastroesophageal Reflux Disease |
Seoul National University Hospital |
December 2009 | Not Applicable |
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
